Liver function after combined selective internal radiation therapy or sorafenib monotherapy in advanced hepatocellular carcinoma.

[1]  H. Amthauer,et al.  Prognostic value of baseline interleukin 6 levels in liver decompensation and survival in HCC patients undergoing radioembolization , 2021, EJNMMI Research.

[2]  H. Amthauer,et al.  Impact of Pharmaceutical Prophylaxis on Radiation-Induced Liver Disease Following Radioembolization , 2021, Cancers.

[3]  M. Graffeo,et al.  Clinical Characterisation and Management of the Main Treatment-Induced Toxicities in Patients with Hepatocellular Carcinoma and Cirrhosis , 2021, Cancers.

[4]  T. de Baère,et al.  Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. , 2020, The lancet. Gastroenterology & hepatology.

[5]  L. Kulik,et al.  Locoregional Therapies for Hepatocellular Carcinoma: What Has Changed in the Past Ten Years? , 2020, Clinics in liver disease.

[6]  M. Imamura,et al.  Trends in Hepatic Functional Reserve of Patients with Hepatocellular Carcinoma Treated with Tyrosine Kinase Inhibitors , 2020, Oncology.

[7]  T. Labeur,et al.  The utility of 99mTc-mebrofenin hepatobiliary scintigraphy with SPECT/CT for selective internal radiation therapy in hepatocellular carcinoma , 2020, Nuclear medicine communications.

[8]  G. Chatellier,et al.  Relationship of Tumor Radiation-absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with 90Y in the SARAH Study. , 2020, Radiology.

[9]  V. Singh,et al.  Pharmacological management of ionizing radiation injuries: current and prospective agents and targeted organ systems , 2020, Expert opinion on pharmacotherapy.

[10]  H. Amthauer,et al.  Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. , 2019, Journal of hepatology.

[11]  T. Labeur,et al.  A Pilot Study on Hepatobiliary Scintigraphy to Monitor Regional Liver Function in 90Y Radioembolization , 2019, The Journal of Nuclear Medicine.

[12]  W. Lau,et al.  Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled Study , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Kudo,et al.  Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child–Pugh A Liver Function: A Proof-Of-Concept Study , 2019, Cancers.

[14]  V. Gebski,et al.  SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Rachida Lebtahi,et al.  Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. , 2017, The Lancet. Oncology.

[16]  B. Sangro,et al.  Prevention and treatment of complications of selective internal radiation therapy: Expert guidance and systematic review , 2017, Hepatology.

[17]  J. Theysohn,et al.  Factors associated with contralateral liver hypertrophy after unilateral radioembolization for hepatocellular carcinoma , 2017, PloS one.

[18]  H. Amthauer,et al.  Cytokines and 90Y-Radioembolization: Relation to Liver Function and Overall Survival , 2017, CardioVascular and Interventional Radiology.

[19]  M. A. van den Bosch,et al.  Radioembolization-induced liver disease: a systematic review , 2017, European journal of gastroenterology & hepatology.

[20]  T. Baker,et al.  Angiogenic Response following Radioembolization: Results from a Randomized Pilot Study of Yttrium-90 with or without Sorafenib. , 2016, Journal of vascular and interventional radiology : JVIR.

[21]  B. Sangro,et al.  Radioembolization of hepatocellular carcinoma activates liver regeneration, induces inflammation and endothelial stress and activates coagulation , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[22]  B. Sangro,et al.  Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  P. Wust,et al.  Radiation-Induced Liver Damage: Correlation of Histopathology with Hepatobiliary Magnetic Resonance Imaging, a Feasibility Study , 2015, CardioVascular and Interventional Radiology.

[24]  P. Wust,et al.  Prospective Randomized Trial of Enoxaparin, Pentoxifylline and Ursodeoxycholic Acid for Prevention of Radiation-Induced Liver Toxicity , 2014, PloS one.

[25]  B. Sangro,et al.  Partial liver volume radioembolization induces hypertrophy in the spared hemiliver and no major signs of portal hypertension. , 2014, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[26]  Mei Yang,et al.  Indocyanine green clearance in evaluating the recovery of liver reserve function after superselective transarterial chemoembolization. , 2013, Hepatobiliary & pancreatic diseases international : HBPD INT.

[27]  J. Prieto,et al.  Prognostic factors and prevention of radioembolization‐induced liver disease , 2013, Hepatology.

[28]  A. Tsung,et al.  Underlying steatohepatitis, but not simple hepatic steatosis, increases morbidity after liver resection: A case‐control study , 2012, Hepatology.

[29]  B. Sangro,et al.  Liver disease induced by radioembolization of liver tumors , 2008, Cancer.

[30]  B. Bell,et al.  The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. , 2006, Journal of hepatology.

[31]  M. Anscher,et al.  Hepatic toxicity resulting from cancer treatment. , 1995, International journal of radiation oncology, biology, physics.

[32]  A. Gown,et al.  Hepatic veno-occlusive disease after bone marrow transplantation. Immunohistochemical identification of the material within occluded central venules. , 1987, The American journal of pathology.

[33]  L. F. Fajardo,et al.  Pathogenesis of veno-occlusive liver disease after radiation. , 1980, Archives of pathology & laboratory medicine.

[34]  Jacob Cohen.  Statistical Power Analysis for the Behavioral Sciences , 1969, The SAGE Encyclopedia of Research Design.

[35]  A. Cox,et al.  The human liver after radiation injury. A form of veno-occlusive disease. , 1966, The American journal of pathology.

[36]  A. Benson,et al.  Radioembolization for hepatocellular carcinoma with portal vein thrombosis: impact of liver function on systemic treatment options at disease progression. , 2013, Journal of hepatology.